Labcorp Holdings Inc. logo

Labcorp Holdings Inc. (LH)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
258. 39
-3.09
-1.18%
$
22.24B Market Cap
- P/E Ratio
2.88% Div Yield
526,513 Volume
- Eps
$ 261.48
Previous Close
Day Range
257.55 261.65
Year Range
209.38 293.72
Want to track LH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 61 days
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion

LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion

Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.

Zacks | 1 year ago
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health

Labcorp Stock Gains From Its Latest Acquisition of BioReference Health

LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.

Zacks | 1 year ago
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes

Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

Zacks | 1 year ago
LH Stock Expected to Gain From the Ballad Health Acquisition Deal

LH Stock Expected to Gain From the Ballad Health Acquisition Deal

Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.

Zacks | 1 year ago
Labcorp says it could ramp up mpox testing capacity

Labcorp says it could ramp up mpox testing capacity

Diagnostics firm Labcorp said it is processing approximately 500 mpox tests a month but have the capacity to process approximately 25,000 per month.

Reuters | 1 year ago
Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.

Zacks | 1 year ago
Labcorp (LH) Gains From New Collaborations Amid FX Issues

Labcorp (LH) Gains From New Collaborations Amid FX Issues

Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.

Zacks | 1 year ago
LabCorp Analysts Boost Their Forecasts After Better-Than-Expected Earnings

LabCorp Analysts Boost Their Forecasts After Better-Than-Expected Earnings

Labcorp Holdings Inc LH reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates on Thursday.

Benzinga | 1 year ago
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)

Labcorp (LH) Q2 Earnings Surpass Estimates (revised)

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Zacks | 1 year ago
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector

LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector

Thursday, Laboratory Corp A reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78.

Benzinga | 1 year ago
Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase

Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Zacks | 1 year ago
Compared to Estimates, Labcorp (LH) Q2 Earnings: A Look at Key Metrics

Compared to Estimates, Labcorp (LH) Q2 Earnings: A Look at Key Metrics

The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Loading...
Load More